DOP2010000222A - 3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa - Google Patents

3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa

Info

Publication number
DOP2010000222A
DOP2010000222A DO2010000222A DO2010000222A DOP2010000222A DO P2010000222 A DOP2010000222 A DO P2010000222A DO 2010000222 A DO2010000222 A DO 2010000222A DO 2010000222 A DO2010000222 A DO 2010000222A DO P2010000222 A DOP2010000222 A DO P2010000222A
Authority
DO
Dominican Republic
Prior art keywords
phenoxi
benzamida
pirrolidin
dimethylphenyl
fluoro
Prior art date
Application number
DO2010000222A
Other languages
English (en)
Spanish (es)
Inventor
Nuria Diaz Buezo
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2010000222A publication Critical patent/DOP2010000222A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DO2010000222A 2008-01-22 2010-07-20 3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa DOP2010000222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25

Publications (1)

Publication Number Publication Date
DOP2010000222A true DOP2010000222A (es) 2015-11-15

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000222A DOP2010000222A (es) 2008-01-22 2010-07-20 3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa

Country Status (32)

Country Link
US (2) US7709522B2 (enExample)
EP (1) EP2252581B1 (enExample)
JP (1) JP5345637B2 (enExample)
KR (1) KR101172170B1 (enExample)
CN (1) CN101925576B (enExample)
AR (1) AR070158A1 (enExample)
AU (1) AU2009206653B2 (enExample)
BR (1) BRPI0907382B8 (enExample)
CA (1) CA2713025C (enExample)
CO (1) CO6290644A2 (enExample)
CY (1) CY1113071T1 (enExample)
DK (1) DK2252581T3 (enExample)
DO (1) DOP2010000222A (enExample)
EA (1) EA017484B1 (enExample)
EC (1) ECSP10010365A (enExample)
ES (1) ES2388708T3 (enExample)
HR (1) HRP20120558T1 (enExample)
IL (1) IL206038A (enExample)
JO (1) JO2797B1 (enExample)
MA (1) MA32751B1 (enExample)
MX (1) MX2010007849A (enExample)
MY (1) MY163014A (enExample)
NZ (1) NZ586225A (enExample)
PE (1) PE20091317A1 (enExample)
PL (1) PL2252581T3 (enExample)
PT (1) PT2252581E (enExample)
SI (1) SI2252581T1 (enExample)
TN (1) TN2010000306A1 (enExample)
TW (1) TWI422369B (enExample)
UA (1) UA100715C2 (enExample)
WO (1) WO2009094260A1 (enExample)
ZA (1) ZA201003908B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422369B (zh) * 2008-01-22 2014-01-11 Lilly Co Eli κ選擇性類鴉片受體拮抗劑
KR20100130596A (ko) * 2008-01-22 2010-12-13 다케다 야쿠힌 고교 가부시키가이샤 부신 피질 자극 호르몬 방출 인자 길항 작용을 갖는 3 환식 화합물 및 이를 함유하는 약학 조성물
WO2013040321A1 (en) 2011-09-15 2013-03-21 University Of Kansas Kappa opioid receptor effectors and uses thereof
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
CA2858752C (en) 2011-12-09 2019-12-31 Research Triangle Institute 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
JP2016519161A (ja) * 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
EP3596069B1 (en) 2017-03-17 2022-07-13 The Scripps Research Institute Kappa opioid receptor antagonists and products and methods related thereto
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
JP2024516297A (ja) 2021-05-04 2024-04-12 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のための組成物及び方法
MX2024008618A (es) * 2022-01-10 2024-09-25 Janssen Pharmaceuticals Inc Composiciones y métodos para el tratamiento de la depresión.
JP2025503649A (ja) * 2022-01-10 2025-02-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のための組成物及び方法
EP4489748A1 (en) * 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
JP2025508069A (ja) * 2022-03-07 2025-03-21 ヤンセン ファーマシューティカルズ，インコーポレーテッド アチカプラントを含む組成物
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) * 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
EP1178990B1 (en) * 1999-05-12 2003-01-29 F. Hoffmann-La Roche Ag Imidazodiazepine derivative
EP1337859A1 (en) * 2000-10-05 2003-08-27 Hanns Mohler Selective anxiolytic therapeutic agents
WO2002049643A1 (en) * 2000-12-21 2002-06-27 The Mclean Hospital Corporation Treatment of depression
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
BR0308918A (pt) * 2002-03-28 2005-01-04 Wisys Technology Found Inc Agentes ansiolìticos com efeitos sedativos e atáxicos reduzidos
PL212616B1 (pl) * 2002-09-19 2012-10-31 Lilly Co Eli Eter diarylowy i kompozycja farmaceutyczna zawierajaca ten eter
BRPI0407616A (pt) 2003-03-07 2006-02-14 Lilly Co Eli composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste"
WO2004080996A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company Opioid receptor antagonists
JP2007516256A (ja) * 2003-12-12 2007-06-21 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
US7381750B2 (en) * 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
ATE399164T1 (de) * 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
AU2005222640A1 (en) * 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
ES2318472T3 (es) * 2004-03-15 2009-05-01 Eli Lilly And Company Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad.
CA2557794A1 (en) * 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
CA2646899C (en) 2006-04-04 2014-05-06 Holger Lars Hermann Use of compositions containing kappa-opioid receptor antagonists for the treatment of dissociative disorders
JP5362565B2 (ja) 2006-08-09 2013-12-11 スミスクライン ビーチャム コーポレーション オピオイド受容体のアンタゴニストまたはインバースアゴニストである新規化合物
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
TWI422369B (zh) * 2008-01-22 2014-01-11 Lilly Co Eli κ選擇性類鴉片受體拮抗劑

Also Published As

Publication number Publication date
MA32751B1 (fr) 2011-11-01
US20100197669A1 (en) 2010-08-05
ECSP10010365A (es) 2010-08-31
HK1146822A1 (en) 2011-07-15
KR20100095639A (ko) 2010-08-31
AU2009206653A1 (en) 2009-07-30
CA2713025A1 (en) 2009-07-30
TN2010000306A1 (en) 2011-11-11
EP2252581A1 (en) 2010-11-24
BRPI0907382B1 (pt) 2020-03-10
IL206038A (en) 2013-11-28
DK2252581T3 (da) 2012-07-16
TW200936129A (en) 2009-09-01
CN101925576B (zh) 2013-02-06
IL206038A0 (en) 2010-11-30
PE20091317A1 (es) 2009-09-03
MX2010007849A (es) 2010-08-09
EA201070877A1 (ru) 2010-12-30
JP5345637B2 (ja) 2013-11-20
TWI422369B (zh) 2014-01-11
EA017484B1 (ru) 2012-12-28
NZ586225A (en) 2012-05-25
US20090186873A1 (en) 2009-07-23
EP2252581B1 (en) 2012-06-20
PL2252581T3 (pl) 2012-10-31
PT2252581E (pt) 2012-08-31
AR070158A1 (es) 2010-03-17
CY1113071T1 (el) 2016-04-13
KR101172170B1 (ko) 2012-08-07
CO6290644A2 (es) 2011-06-20
US7709522B2 (en) 2010-05-04
AU2009206653B2 (en) 2013-07-18
UA100715C2 (ru) 2013-01-25
HRP20120558T1 (hr) 2012-10-31
CA2713025C (en) 2012-12-04
MY163014A (en) 2017-07-31
BRPI0907382B8 (pt) 2021-05-25
JO2797B1 (en) 2014-03-15
CN101925576A (zh) 2010-12-22
ZA201003908B (en) 2011-11-30
ES2388708T3 (es) 2012-10-17
BRPI0907382A2 (pt) 2015-07-21
SI2252581T1 (sl) 2012-09-28
WO2009094260A1 (en) 2009-07-30
US8173695B2 (en) 2012-05-08
JP2011524850A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
DOP2010000222A (es) 3-fluoro-4-[4-[2-(3,5-dimetilfenil)pirrolidin-1-il-metil]fenoxi]benzamida, antagonista del receptor opioide selectivo kappa
AR079198A1 (es) Sales de 4-(2-((5-metil-1-(2-naftalenil) -1h pirazol -3- il)oxi) etil) morfolina
TNSN08089A1 (en) Substituted benzimidazoles and methods of preparation
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
CO6210732A2 (es) Indazoles sustituidos con amina como inhibidores de poli(adp-ribosa) polimerasa (parp)
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
CO6592093A2 (es) Polimorfos y solvatos de clorhidrato de 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi9etil)morfolina
CR10249A (es) Compuestos de amino- pirimidina 2,6-sistituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
ES2723277T3 (es) Una forma sólida de clorhidrato de (S)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
MX2010001837A (es) Derivados de 4-pirimidinasulfamida.
UY32331A (es) Compuestos novedosos como ligandos de receptores de canabinoides
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
HRP20182059T1 (hr) Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja
DOP2010000078A (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3
PE20160846A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c
CL2011002345A1 (es) Proceso de obtencion del acido (s)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxazol-4-il)-etoxi]-benzo[b]tiofen-7-il}-propionico utilizando un catalizador de iridio.
CL2017000069A1 (es) Derivado de hidantoina.
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
AR077223A1 (es) Sales de fumarato de un antagonista del receptor de histamina h3
CR11559A (es) Antagonista del receptor opioide selectivo kappa
ECSP12011833A (es) Proceso para la elaboración de compuestos orgánicos
EA201390966A1 (ru) Замещенные соединения [(5h-пирроло[2,1-c][1,4]бензодиазепин-11-ил)пиперазин-1-ил]-2,2-диметилпропановой кислоты в качестве обратных агонистов h1/антагонистов 5-htдвойного действия
MX2011011177A (es) Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina.
EP2409966A4 (en) AMINOCYCLITOL COMPOUNDS, METHOD FOR THEIR OBTAINMENT AND USES THEREOF
HN2010001319A (es) Antagonista del receptor opioide selectivo kappa